Polymeric cryogel for the removal of heparins and heparinoids from aqueous solutions, physiological solutions and biological fluids

# Record card
50
Thematic areas
Chemicals & Physics / Separation technologies
Health & Biotech / Medical Device
Materials / Plastics, polymers
Description

This technology describe the synthesis of cross-linked polymeric materials in the form of macroporous gels based on poly (2-hydroxyethyl methacrylate), capable of sequestering the anticoagulant heparin from aqueous solutions, physiological solutions and biological fluids. They are morphologically elastic and mechanically stable materials, and show high specificity and selectivity for heparin as demonstrated by the negligible adsorption of specific blood proteins such as antithrombin III, albumin and total proteins. Preliminary tests to assess blood compatibility have also shown that macroporous hydrogels do not activate hemolysis, complement C3 and do not interfere with leukocyte and platelet counts. For these properties they could find a real application in the development of blood filters useful in surgery and dialysis to restore normal coagulation parameters after the use of heparin. The development of such devices could make more controllable the hemorrhagic events occasionally occurring during major surgeries, and, for patients that undergo to hemodialysis, could limit the onset of diseases caused by chronic use of heparin.

Business fields
Industry
Type of innovation
Product innovation
Description of innovative features / Competitive advantages

The development of these filters could bring significant improvements to the  safety and quality life of patients who undergo  the anticoagulant. Assuming the insertion of a hypothetical neutralizing filter in the circuit of the extracorporeal circulation machine, before the blood re-enters the circulation, the side effects and hemorrhagic risks could be eliminated. Moreover, also the risks  due to protamine administration, the only antidote to heparin currently used,  would be avoided. In fact, to the best of our knowledge, despite the numerous efforts evidenced by the dedicated literature, coagulation control is still regulated by protocols that afford  the use of protamine. The only device, recently marketed, which allows the correct execution of dialysis using lower doses of heparin, is a dialyzer consisting of a heparinized membrane, whose use is reserved only for patients with a high risk of bleeding. The hypothetical filter proposed, also due to the low cost of the raw materials, could be developed as a disposable device, and usually be placed side by side with machines for extracorporeal blood circulation.

Reference market
Total innovation
Impacts on existing markets
Development stage
Feasibility
TRL
4
Advantages
New product/process/service/technology
Patented technology
Yes
Country/ies

Italy, EPO, USA

Market positioning
Italian
European
International
Partner required
Enteprise
Private research center

Information
For more information and/or to be put in contact with the Research Team, please contact the Project Manager:

Barbara Angelini - Project Manager
CNR - Unità Valorizzazione della Ricerca
Phone number 06.49932415
E-mail barbara.angelini@cnr.it